核糖核酸
计算生物学
小分子
药物发现
质谱法
化学
生物
遗传学
生物信息学
基因
色谱法
作者
Noreen F. Rizvi,Elliott Nickbarg
出处
期刊:Methods
[Elsevier]
日期:2019-05-03
卷期号:167: 28-38
被引量:24
标识
DOI:10.1016/j.ymeth.2019.04.024
摘要
Recent advances resulting from the completion of the human genome have shown that RNA has the promise to be a target for small molecule drugs, and therefore represents a previously unexploited class of targets for novel human therapeutics. We recently reported the adaptation of an affinity selection mass spectrometry screening technique, termed ALIS (Automatic Ligand Identification System), to screen and characterize a variety of RNA species from both prokaryotic and eukaryotic sources. We demonstrated that the ALIS technique, which had previously been used for protein targets, was also compatible for screening, ranking and characterizing small molecule ligands for RNA targets. We present here a detailed description of the use of ALIS for screening and characterizing ligands for RNA and discuss issues of validating and testing RNA for use in the ALIS system. We have also further elaborated on issues of RNA stability and testing in the ALIS system and demonstrate that the affinity-selection screening system has the potential to be a general solution for label-free screening and characterization of small molecule drug candidates for RNA targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI